Nishida Hayato, Fukuhara Hiroki, Takai Satoshi, Nawano Takaaki, Takehara Tomohiro, Narisawa Takafumi, Kanno Hidenori, Yagi Mayu, Yamagishi Atsushi, Naito Sei, Tsuchiya Norihiko
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Int J Urol. 2025 Jan;32(1):88-93. doi: 10.1111/iju.15600. Epub 2024 Oct 7.
We evaluated whether a history of low-dose rituximab treatment affected herpes zoster development after living kidney transplantation.
We enrolled 103 living kidney transplant recipients. Patients were divided into two groups according to their history of rituximab treatment; rituximab was administered to 50 living kidney transplant recipients. We assessed the difference in herpes zoster events between the two groups and determined the risk factors for herpes zoster using multivariate regression analysis.
The total dose of rituximab in each kidney transplant recipient who received rituximab therapy was 200-400 mg. The rate of herpes zoster events after transplantation in recipients who received rituximab therapy (4 of 50, 8%) was not higher than that in recipients who did not receive rituximab (9 of 53, 17%) (p = 0.238). Herpes zoster-free survival did not significantly differ between the two groups (p = 0.409). In the multivariate regression analysis, the association between varicella zoster vaccination before transplantation and herpes zoster events after transplantation was confirmed, whereas rituximab therapy was not associated with herpes zoster events.
Low-dose rituximab therapy in kidney transplant recipients did not influence herpes zoster development after transplantation. Varicella zoster vaccination before transplantation may play an important role in preventing herpes zoster after transplantation.
我们评估了低剂量利妥昔单抗治疗史是否会影响活体肾移植后带状疱疹的发生。
我们纳入了103名活体肾移植受者。根据利妥昔单抗治疗史将患者分为两组；50名活体肾移植受者接受了利妥昔单抗治疗。我们评估了两组之间带状疱疹事件的差异，并使用多因素回归分析确定了带状疱疹的危险因素。
接受利妥昔单抗治疗的每位肾移植受者的利妥昔单抗总剂量为200 - 400毫克。接受利妥昔单抗治疗的受者移植后带状疱疹事件发生率（50例中有4例，8%）不高于未接受利妥昔单抗治疗的受者（53例中有9例，17%）（p = 0.238）。两组之间无带状疱疹生存期无显著差异（p = 0.409）。在多因素回归分析中，证实了移植前水痘带状疱疹疫苗接种与移植后带状疱疹事件之间的关联，而利妥昔单抗治疗与带状疱疹事件无关。
肾移植受者的低剂量利妥昔单抗治疗不会影响移植后带状疱疹的发生。移植前接种水痘带状疱疹疫苗可能在预防移植后带状疱疹方面发挥重要作用。
